RxDoctor Payments Data

Damon Pettinelli, MD

Ophthalmology · Baltimore, MDNPI 1558477448

Payments from drug & device makers

$3,539in general payments, 2019–2025

Across 221 payments — averaging $16.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AbbVie$648
  • Sun Pharmaceutical Industries Inc.$194
  • Oyster Point Pharma, Inc.$93
  • Aerie Pharmaceuticals, Inc.$74
  • Johnson & Johnson Surgical Vision, Inc.$61
  • plus $281 from 7 others

What the payments were for

  • Food & beverage$3,539100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,539 in reported general payments places this provider in the 70th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$170,071
Medicare patients
443
Services billed
1,541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine509$496,106
XiidraLifitegrast444$379,853
LumiganBimatoprost468$272,373
CombiganBrimonidine Tartrate/Timolol183$80,285
Alphagan PBrimonidine Tartrate65$26,601
RocklatanNetarsudil Mesylat/Latanoprost65$23,914
SimbrinzaBrinzolamide/Brimonidine Tart97$20,527
Prednisolone Acetate371$19,428
CequaCyclosporine28$16,479
RhopressaNetarsudil Mesylate44$16,181
Latanoprost1,859$16,137
MieboPerfluorohexyloctane/Pf20$15,812
VyzultaLatanoprostene Bunod32$14,010
Cyclosporine28$10,198
Travatan ZTravoprost12$7,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$648$875,3651,225 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$60$409,676496 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$74$40,095109 claims
AlconSimbrinza$2,188$20,52797 claims
Sun Pharmaceutical Industries Inc.Cequa$194$16,47928 claims
NovartisTravatan Z$57$7,62712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →